Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Nair
J S
JS
Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, New York 10595, USA.
Kancherla
R
R
Seiter
K
K
Traganos
F
F
Tse-Dinh
Y C
YC
D000208:Acute Disease; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology*; D017321:Clinical Trials, Phase I as Topic; D003561:Cytarabine / Q000008:administration & dosage; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000378:metabolism; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism; D004273:DNA, Neoplasm / Q000097:blood / Q000378:metabolism; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology*; D007962:Leukocytes / Q000378:metabolism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000201:enzymology*; D008942:Mitoxantrone / Q000008:administration & dosage; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis / Q000097:blood / Q000235:genetics; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan / Q000008:administration & dosage
D000951:Antigens, Neoplasm; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D012333:RNA, Messenger; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D005047:Etoposide; D019772:Topotecan; D008942:Mitoxantrone; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II